1. Arnon, R., 1979, Anti-tumor antibodies as carriers for anti-cancer drugs, in:“Tumor-associated antigens and their specific immune response, F. Spreafico and R. Arnon, eds., Academic Press, New York.
2. Bergman, Y., and Haimovich, J., 1977, Characterization of a carcino- gen-induced murine B lymphocyte cell line of C3H/eB origin, Eur. J. Immunol. 7: 413.
3. Bernstein, A., Hurwitz, E., Maron, R., Arnon, R., Sela, M., and Wilchek, M., 1978, Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies, J. Natl. Cancer Inst. 60: 379.
4. Blythman, H.E., Casellas, P., Gros, O., Gros, P., Jansen, F.K., Paolucci, F., Pau, B., and Vidal, H., 1981, Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumor cells, Nature 290: 145.
5. Davies, D.A.L., and O’Neil, G.J., 1973, In vivo and in vitro effects of tumor specific antibodies with chlorambucil, Br. J. Cancer 28: Suppl. I, 285.